Whole exome sequencing in relapsed or refractory childhood cancer: case series.

Thangpong, Rungroj; Nuwongsri, Pattarin; Ittiwut, Chupong; Ittiwut, Rungnapa; Phokaew, Chureerat; Techavichit, Piti; Suphapeetiporn, Kanya

Thangpong, Rungroj; Nuwongsri, Pattarin; Ittiwut, Chupong; Ittiwut, Rungnapa; Phokaew, Chureerat; Techavichit, Piti; Suphapeetiporn, Kanya.

Afiliação

Thangpong R; Department of Pediatrics, Faculty of Medicine, Chulalongkorn University, Bangkok 10330, Thailand.
Nuwongsri P; Excellence Center for Genomics and Precision Medicine, King Chulalongkorn Memorial Hospital, the Thai Red Cross Society, Bangkok 10330, Thailand.
Ittiwut C; Excellence Center for Genomics and Precision Medicine, King Chulalongkorn Memorial Hospital, the Thai Red Cross Society, Bangkok 10330, Thailand.
Ittiwut R; Center of Excellence for Medical Genomics, Medical Genomics Cluster, Department of Pediatrics, Faculty of Medicine, Chulalongkorn University, Bangkok 10330, Thailand.
Phokaew C; Excellence Center for Genomics and Precision Medicine, King Chulalongkorn Memorial Hospital, the Thai Red Cross Society, Bangkok 10330, Thailand.
Techavichit P; Center of Excellence for Medical Genomics, Medical Genomics Cluster, Department of Pediatrics, Faculty of Medicine, Chulalongkorn University, Bangkok 10330, Thailand.
Suphapeetiporn K; Center of Excellence for Medical Genomics, Medical Genomics Cluster, Department of Pediatrics, Faculty of Medicine, Chulalongkorn University, Bangkok 10330, Thailand.

Asian Biomed (Res Rev News) ; 18(4): 186-191, 2024 Aug.

Article em En | MEDLINE | ID: mdl-39309469

ABSTRACT

ABSTRACT

Background:

The prognosis for relapsed or refractory childhood cancer is approximately 20%. Genetic alterations are one of the significant contributing factors to the prognosis of patients.

Objective:

To investigate the molecular profile of relapsed or refractory childhood cancers in Thai cases.

Methods:

The study design is a descriptive study of patients <18 years old, suspected or diagnosed of relapsed or refractory childhood cancer who underwent whole exome sequencing (WES).

Results:

WES was successfully performed in both the tumor and the blood or saliva samples obtained from 4 unrelated patients. Six different variants were identified in the NCOR2, COL6A3, TP53, and SMAD4 genes. These alterations were found to be associated with tumor aggressiveness.